Dosage and Duration of Methylprednisolone Therapy Affect the Occurrence of Cushing Habitus in Patients with Systemic Lupus Erythematosus.
Cushing habitus
daily dose
pulse dose
total dose
Journal
Journal of pharmacy & bioallied sciences
ISSN: 0976-4879
Titre abrégé: J Pharm Bioallied Sci
Pays: India
ID NLM: 101537209
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
20
09
2019
accepted:
01
11
2019
entrez:
10
3
2020
pubmed:
10
3
2020
medline:
10
3
2020
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE) is a multisystem disease with very diverse developments. Corticosteroid is mostly used for the treatment of SLE as antiinflammatory and immunosuppressant, but its long-term use and high dose can cause the side effects such as Cushing habitus. Analyze the risk factors of Cushing habitus occurrence in patients with SLE comprising pulse dose, duration of therapy, daily dose, and total dose of methylprednisolone. Case Control study. 40 patients with SLE treated at Rheumatology outpatient clinic at Hasan Sadikin Hospital in Bandung was conducted. Each of these patients were divided into case and control groups. The design of this study was a case control study, the data was retrieved from medical record of patients with and without cushing habitus. Chi-squared test was used to test the relationship between independent variables followed by linear logistic regression analysis to determine the influence of the most influential variable in causing Cushing habitus. The results of this study showed that the use of total dose of methylprednisolon (> 8040 mg) has a significant effect on the incidence of Cushing habitus Significant relationship between daily dose and total dose of methylprednisolone on the occurrence of Cushing.
Identifiants
pubmed: 32148374
doi: 10.4103/jpbs.JPBS_212_19
pii: JPBS-11-628
pmc: PMC7020842
doi:
Types de publication
Journal Article
Langues
eng
Pagination
S628-S634Informations de copyright
Copyright: © 2019 Journal of Pharmacy and Bioallied Sciences.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Eur J Intern Med. 2012 Apr;23(3):278-82
pubmed: 22385888
J Dermatol. 1999 Feb;26(2):122-4
pubmed: 10091484
Lupus. 2014 Mar;23(3):327-34
pubmed: 24297642
Neurohospitalist. 2013 Apr;3(2):92-7
pubmed: 23983891
Ann Rheum Dis. 2009 Jul;68(7):1119-24
pubmed: 18684744
Indian J Pediatr. 2008 Oct;75(10):1057-66
pubmed: 19023530
Clin Epidemiol. 2015 Apr 17;7:281-93
pubmed: 25945066
Lupus. 2007;16(6):387-93
pubmed: 17664228
Eur J Endocrinol. 2018 Mar;178(3):L3
pubmed: 29440268
Arthritis Care Res (Hoboken). 2016 Jun;68(6):819-27
pubmed: 26473719
Rheumatology (Oxford). 2012 Jul;51(7):1145-53
pubmed: 22271756